World Pharma News Digest - 27.01.2014
1 view
Skip to first unread message
Ruslan David
Jan 27, 2014, 5:24:45 AM1/27/14
to worldph...@googlegroups.com
Bristol-Myers Squibb Reports fourth quarter and full year 2013 financial results
Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) has reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model.
Read more...
http://www.worldpharmanews.com/bms/2681-bristol-myers-squibb-reports-fourth-quarter-and-full-year-2013-financial-results
All FDA drug approvals not created equal
Many patients and physicians assume that the safety and effectiveness of newly approved drugs is well understood by the federal Food and Drug Administration (FDA) - but a new study by researchers at Yale School of Medicine shows that the clinical trials used by the FDA to approve new drugs between 2005 and 2012 vary widely in their thoroughness. Published in the Jan. 22/29 issue of JAMA, the study is the first systematic analysis of the standard used by the FDA in making drug approval decisions.
Read more...
http://www.worldpharmanews.com/research/2680-all-fda-drug-approvals-not-created-equal
Researchers discover potential drug targets for early onset glaucoma
Using a novel high-throughput screening process, scientists have for the first time identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma. Researchers have implicated a mutant form of a protein called myocilin as a possible root cause of this increased eye pressure. Mutant myocilin is toxic to the cells in the part of the eye that regulates pressure.
Read more...
http://www.worldpharmanews.com/research/2679-researchers-discover-potential-drug-targets-for-early-onset-glaucoma
Abbott reports fourth-quarter and full-year 2013 results
Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2013. Fourth-quarter 2013 worldwide sales of $5.7 billion increased 3.3 percent on an operational basis, driven by Diagnostics and Medical Devices. On a reported basis, sales increased 0.4 percent, including an unfavorable 2.9 percent effect of foreign exchange.
Read more...
http://www.worldpharmanews.com/abbott/2678-abbott-reports-fourth-quarter-and-full-year-2013-results
Breakthrough announced in treatment of patient with rare type of leukemia
A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer. The research, published in the New England Journal of Medicine, indicates Vemurafenib, a BRAF inhibitor that has been approved as a treatment for advanced melanomas, is also successful in treating leukaemia.
Read more...
http://www.worldpharmanews.com/research/2677-breakthrough-announced-in-treatment-of-patient-with-rare-type-of-leukemia
Boosting vitamin D could slow progression, reduce severity of multiple sclerosis
For patients in the early stages of multiple sclerosis (MS), low levels of vitamin D were found to strongly predict disease severity and hasten its progression, according to a new study led by Harvard School of Public Health (HSPH) investigators in collaboration with Bayer HealthCare. The findings suggest that patients in the early stages of MS could stave off disease symptoms by increasing their vitamin D intake.
Read more...
http://www.worldpharmanews.com/research/2676-boosting-vitamin-d-could-slow-progression-reduce-severity-of-multiple-sclerosis
PharmaNews.eu / Latest News
Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF)
http://www.pharmanews.eu/novartis/1393-novartis-to-request-re-examination-of-serelaxin-rlx030-in-acute-heart-failure-ahf
Researchers discover simple amoeba holds the key to better treatment for Alzheimer's
http://www.pharmanews.eu/research-and-development/1392-researchers-discover-simple-amoeba-holds-the-key-to-better-treatment-for-alzheimers
ViiV Healthcare's new HIV medicine TivicayTM (dolutegravir) is approved in Europe
http://www.pharmanews.eu/gsk/1391--viiv-healthcares-new-hiv-medicine-tivicaytm-dolutegravir-is-approved-in-europe
Leaving home: Beta cells' way to maturity
http://www.pharmanews.eu/research-and-development/1389-leaving-home-beta-cells-way-to-maturity
Leukemia: mode of action of a targeted treatment clarified
http://www.pharmanews.eu/research-and-development/1390-leukemia-mode-of-action-of-a-targeted-treatment-clarified
Top Portuguese and Finnish scientists to lead IMI Scientific Committee
http://www.pharmanews.eu/research-and-development/1388-top-portuguese-and-finnish-scientists-to-lead-imi-scientific-committee
PRAC recommends suspending use of Protelos/Osseor
http://www.pharmanews.eu/ema/1387-prac-recommends-suspending-use-of-protelososseor
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please download World Pharma News' Media Pack: http://www.worldpharmanews.com/contact-us
Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) has reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model.
Read more...
http://www.worldpharmanews.com/bms/2681-bristol-myers-squibb-reports-fourth-quarter-and-full-year-2013-financial-results
All FDA drug approvals not created equal
Many patients and physicians assume that the safety and effectiveness of newly approved drugs is well understood by the federal Food and Drug Administration (FDA) - but a new study by researchers at Yale School of Medicine shows that the clinical trials used by the FDA to approve new drugs between 2005 and 2012 vary widely in their thoroughness. Published in the Jan. 22/29 issue of JAMA, the study is the first systematic analysis of the standard used by the FDA in making drug approval decisions.
Read more...
http://www.worldpharmanews.com/research/2680-all-fda-drug-approvals-not-created-equal
Researchers discover potential drug targets for early onset glaucoma
Using a novel high-throughput screening process, scientists have for the first time identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma. Researchers have implicated a mutant form of a protein called myocilin as a possible root cause of this increased eye pressure. Mutant myocilin is toxic to the cells in the part of the eye that regulates pressure.
Read more...
http://www.worldpharmanews.com/research/2679-researchers-discover-potential-drug-targets-for-early-onset-glaucoma
Abbott reports fourth-quarter and full-year 2013 results
Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2013. Fourth-quarter 2013 worldwide sales of $5.7 billion increased 3.3 percent on an operational basis, driven by Diagnostics and Medical Devices. On a reported basis, sales increased 0.4 percent, including an unfavorable 2.9 percent effect of foreign exchange.
Read more...
http://www.worldpharmanews.com/abbott/2678-abbott-reports-fourth-quarter-and-full-year-2013-results
Breakthrough announced in treatment of patient with rare type of leukemia
A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer. The research, published in the New England Journal of Medicine, indicates Vemurafenib, a BRAF inhibitor that has been approved as a treatment for advanced melanomas, is also successful in treating leukaemia.
Read more...
http://www.worldpharmanews.com/research/2677-breakthrough-announced-in-treatment-of-patient-with-rare-type-of-leukemia
Boosting vitamin D could slow progression, reduce severity of multiple sclerosis
For patients in the early stages of multiple sclerosis (MS), low levels of vitamin D were found to strongly predict disease severity and hasten its progression, according to a new study led by Harvard School of Public Health (HSPH) investigators in collaboration with Bayer HealthCare. The findings suggest that patients in the early stages of MS could stave off disease symptoms by increasing their vitamin D intake.
Read more...
http://www.worldpharmanews.com/research/2676-boosting-vitamin-d-could-slow-progression-reduce-severity-of-multiple-sclerosis
PharmaNews.eu / Latest News
Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF)
http://www.pharmanews.eu/novartis/1393-novartis-to-request-re-examination-of-serelaxin-rlx030-in-acute-heart-failure-ahf
Researchers discover simple amoeba holds the key to better treatment for Alzheimer's
http://www.pharmanews.eu/research-and-development/1392-researchers-discover-simple-amoeba-holds-the-key-to-better-treatment-for-alzheimers
ViiV Healthcare's new HIV medicine TivicayTM (dolutegravir) is approved in Europe
http://www.pharmanews.eu/gsk/1391--viiv-healthcares-new-hiv-medicine-tivicaytm-dolutegravir-is-approved-in-europe
Leaving home: Beta cells' way to maturity
http://www.pharmanews.eu/research-and-development/1389-leaving-home-beta-cells-way-to-maturity
Leukemia: mode of action of a targeted treatment clarified
http://www.pharmanews.eu/research-and-development/1390-leukemia-mode-of-action-of-a-targeted-treatment-clarified
Top Portuguese and Finnish scientists to lead IMI Scientific Committee
http://www.pharmanews.eu/research-and-development/1388-top-portuguese-and-finnish-scientists-to-lead-imi-scientific-committee
PRAC recommends suspending use of Protelos/Osseor
http://www.pharmanews.eu/ema/1387-prac-recommends-suspending-use-of-protelososseor
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please download World Pharma News' Media Pack: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages